BioSpace News Archive

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share

The following quote is attributed to Peter Marks, M.D., Ph.D., Director of FDA’s Center for Biologics Evaluation and Research:

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.

--Multiple Clinical Development Milestones Anticipated in 2021-- --MEI Maintains Strong Financial Position with $180 Million in Cash--

Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively Mitsubishi Tanabe Pharma Corporation (MTPC) Reports Successful Top-Line Results for Asia-Based J-KINECT Phase III Study to Evaluate the Efficacy and Safety of Valbenazine in Tardive Dyskinesia

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results. Conference Call and Webcast Details

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that company management will participate at two upcoming investor conferences:

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies.

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Susanne L. Meline to its Board of Directors, effective January 31, 2021. Her appointment expands Board membership to seven. Ms. Meline has an extensive background in finance, law and corporate governance with more than 20